Acrivon Therapeutics Inc. (ACRV): Price and Financial Metrics
ACRV Price/Volume Stats
| Current price | $8.47 | 52-week high | $14.30 |
| Prev. close | $9.50 | 52-week low | $3.19 |
| Day low | $7.80 | Volume | 698,500 |
| Day high | $10.12 | Avg. volume | 608,486 |
| 50-day MA | $6.48 | Dividend yield | N/A |
| 200-day MA | $7.19 | Market Cap | 191.74M |
ACRV Stock Price Chart Interactive Chart >
Latest ACRV News From Around the Web
Below are the latest news stories about ACRIVON THERAPEUTICS INC that investors may wish to consider to help them evaluate ACRV as an investment opportunity.
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian CancerThe ACR-368-tailored OncoSignature assay is being used in Acrivon’s ongoing registrational-intent Phase 2 trial to predict patients most likely to respond to the CHK1/2 inhibitor ACR-368 in three tumor types Drug-tailored, proprietary OncoSignature assays are developed using the Acrivon Predictive Precision Proteomics (AP3) platform which is also used more broadly to uncover resistance mechanisms and rational drug combinations, and for biological rational drug design for Acrivon’s drug candidate |
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare ConferenceWATERTOWN, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the company’s president and chief |
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WATERTOWN, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, announced that the company approved a grant of equ |
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsWATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the third quarter ended September 30, 2023 and provided busin |
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsData presented on the application of Acrivon Predictive Precision Proteomics (AP3) for the successful development and extensive evaluation of the ACR-368-tailored, proteomics-based OncoSignature assay for the prediction of patients, as well as tumor types, most likely to respond to the CHK1/2 inhibitor ACR-368 ACR-368 OncoSignature assay being utilized in the registrational-intent Phase 2 trial of ACR-368 for patients with ovarian, endometrial, or bladder cancer WATERTOWN, Mass., Oct. 16, 2023 ( |
ACRV Price Returns
| 1-mo | 31.01% |
| 3-mo | 121.73% |
| 6-mo | 68.73% |
| 1-year | -31.14% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 72.15% |
| 2023 | -57.29% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...